-
Aventis Pharma S.A. et al v. Hospira Inc. DC CAFC
- 1:07-cv-00721
- D. Del.
- Judge: Gregory M. Sleet
- Filed: 11/09/2007
- Closed: 09/28/2010
- Latest Docket Entry: 10/10/2013
- PACER
2
Plaintiffs
3
Defendants
1
Accused
Product
2
Patents-in-Suit
1,055
Days in
Litigation
-
Aventis Pharma S.A. et al v. Hospira Inc. DC CAFC
- 1:07-cv-00721
- D. Del.
- Judge: Gregory M. Sleet
- Filed: 11/09/2007
- Closed: 09/28/2010
- Latest Docket Entry: 10/10/2013
- PACER
Market Sector
Biotech and Pharma
Court
Assigned Judge
Outcome Summary
- Patent Information
-
Validity & Enforceability
| Claim | Outcome |
|---|---|
| All challenged claims |
Invalid (103) and Unenforceable
Entry 398 |
| Claim # | Claim Text | Outcome |
|---|---|---|
| 2 |
A composition according to claim 1, wherein, in the compound of formula (I), R represents a hydrogen atom and R.sub.1 represents a tert-butoxycarbonylamino radical.
|
Invalid (103 and 112) and Unenforceable
Entry 398 |
| 10 |
The composition of claim 8 wherein said taxane derivative is taxotere or an analogue or derivative thereof.
|
Invalid (103 and 112) and Unenforceable
Entry 398 |
-
Infringement
Hospira Incorporated
- 2 Details
| Accused Product | Patent # | Claim # | Outcome |
|---|---|---|---|
| Docetaxel injection | US 5,714,512 A |
33
|
Infringement
Entry 398
|
| Docetaxel injection | US 5,750,561 A |
2, 5, 10
|
Infringement
Entry 398
|
